Effect of citicoline versus placebo on clinical signs in patients with acute ischemic and hemorrhagic stroke
Phase 2
- Conditions
- stroke.Stroke, not specified as haemorrhage or infarction
- Registration Number
- IRCT201601289014N90
- Lead Sponsor
- Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
(a) age of 18 to 85 years; (b) acute stroke; (c) NIHSS score between 6 to 22.
Exclusion criteria: (a) previous history of stroke; (b) renal or liver failure; (c) cancer; (d) active infectious disease during last month; (e) trauma or surgery during last month; (f) history of collagen vascular disease; (g) immunosuppressive medications or corticosteroid; (h) signs of brain hernia; (i) convulsion at the time of stroke; (j) neurologic disease or dementia; (k) pregnancy or breastfeeding; (l) receiving vasodilator medications.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measuring stroke score (NIHSS ). Timepoint: at baseline and 10 and 90 days after intervention. Method of measurement: based on NIHSS.;Measuring stroke score (Barthel Index). Timepoint: at baseline and 10 and 90 days after intervention. Method of measurement: based on Barthel Index.;Measuring stroke score (Modified Rankin Scale). Timepoint: at baseline and 10 and 90 days after intervention. Method of measurement: based on Modified Rankin Scale.
- Secondary Outcome Measures
Name Time Method